Welcome to our dedicated page for Perspective Therapeutics SEC filings (Ticker: CATX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Perspective Therapeutics filings document a clinical-stage radiopharmaceutical oncology business built around Lead-212 targeted therapy, imaging diagnostics, and regional manufacturing capabilities. Form 8-K reports include clinical-program exhibits, corporate presentations, preliminary financial information, and annual results for its VMT-α-NET, VMT01, and PSV359 programs.
The company’s SEC record also covers capital-structure matters, including common stock and pre-funded warrant offerings under a shelf registration statement, as well as material agreements, proxy disclosures on board matters, executive compensation, equity awards, shareholder voting items, governance, and other public-company reporting obligations.
Perspective Therapeutics, Inc. filed a current report to note that it updated its corporate presentation on June 1, 2026 and furnished it as Exhibit 99.1. The presentation highlights a strategy focused on next-generation radiopharmaceuticals using the 212Pb isotope to treat solid tumors through a theranostic approach and integrated isotope production.
The deck describes regional daily production and direct-to-hospital delivery, along with a wholly owned 212Pb-based oncology portfolio. Key programs include VMT-α-NET for SSTR2+ neuroendocrine tumors, VMT01 for melanoma, and PSV359 targeting FAP-ɑ in solid tumors, all in ongoing Phase 1/2a or early clinical trials, with references to safety, exposure, and preliminary anti-tumor activity.
Perspective Therapeutics, Inc. reported the results of its 2026 Annual Meeting of Stockholders. Of 114,017,755 common shares entitled to vote, 97,882,462 shares were represented, an 85.85% quorum. Stockholders elected six directors to serve until the 2027 annual meeting.
They also ratified WithumSmith+Brown, PC as independent registered public accounting firm for the fiscal year ending December 31, 2026. In an advisory vote on the frequency of say-on-pay, a one-year interval received the most support, and the company intends to hold annual advisory votes on executive compensation.
Perspective Therapeutics reported interim clinical results that will be highlighted at the 2026 ASCO meeting for all three of its 212Pb radiopharmaceutical programs. Updated data for [212Pb]VMT-α-NET in neuroendocrine tumors show a safety profile without dose-limiting toxicities or serious renal complications across 64 treated patients, and investigator-assessed responses in multiple cohorts with continued deepening of tumor shrinkage over time.
In metastatic melanoma, the [212Pb]VMT01 3.0 mCi monotherapy cohort showed two confirmed responders among seven heavily pre-treated patients, with six experiencing stable disease or partial response and no dose-limiting toxicities or Grade 4–5 events. For [212Pb]PSV359 in FAP-positive solid tumors, treatment has advanced to Cohort 3 at 6.0 mCi, with earlier cohorts showing only Grade 1–2 adverse events and no dose-limiting toxicities. Overall, the company emphasizes that all three programs remain well-tolerated and plans further data updates in late 2026.
Perspective Therapeutics, Inc. amendment to a Schedule 13G shows Morgan Stanley reporting shared voting power of 2,930,734 shares and shared dispositive power of 2,959,296 shares in the issuer's common stock. The filing states the position equals 2.6% of the class.
The filing includes the statement, verbatim, that "As of the date hereof, Morgan Stanley has ceased to be the beneficial owner of more than five percent of the class of securities." The form lists CUSIP 46489V302 and is signed by an authorized Morgan Stanley signatory on 05/12/2026.
Perspective Therapeutics reported a larger net loss as it ramped up development of its radiopharmaceutical pipeline in the quarter ended March 31, 2026. Net loss was $26.2 million, or $0.25 per share, compared with $18.2 million a year earlier, driven mainly by higher research and development spending.
Research and development expense rose to $21.4 million from $14.3 million as the company advanced its VMT-α-NET, VMT01 and PSV359 clinical programs and expanded manufacturing capacity. General and administrative costs eased slightly to $7.0 million from $7.8 million.
Cash, cash equivalents and short-term investments reached $270.9 million, helped by a February 2026 underwritten offering that generated about $175.0 million in gross proceeds. Management believes this cash position can fund planned operations and clinical milestones into late 2027 while it continues to invest in facilities and equipment for future commercial-scale production.
Perspective Therapeutics reported first-quarter 2026 results and highlighted progress across its 212Pb radiopharmaceutical pipeline. Cash, cash equivalents and short-term investments were about $271 million as of March 31, 2026, up from $145 million at year-end 2025, helped by a February underwritten offering that generated roughly $164 million in net proceeds. Management believes this cash should fund current clinical milestones and operations into late 2027.
Research and development expenses rose to $21.4 million from $14.3 million a year earlier as the company expanded staff and clinical and manufacturing activities. General and administrative costs declined to $7.0 million from $7.8 million. Net loss widened to $26.2 million, or $0.25 per share, compared with a loss of $18.2 million, or $0.25 per share, in 2025.
The company reported three clinical-stage programs in neuroendocrine tumors, melanoma and FAP-positive solid tumors, with multiple data and follow-up milestones expected in 2026. It is also expanding a regional manufacturing network, including a flagship Chicago facility planned to complete construction in 2026.
Perspective Therapeutics, Inc. posted an analyst presentation to its website that includes preliminary, estimated financial information and extensive updates on its clinical and manufacturing strategy in targeted oncology. The slides cover its 212Pb-based theranostic programs, including VMT-α-NET for SSTR2+ neuroendocrine tumors and meningioma, along with early data, case studies and treatment landscape context. The presentation also highlights the company’s integrated isotope production, regional manufacturing model and direct-to-hospital delivery aimed at supporting daily production and broad market reach. All financial estimates, including estimated cash, cash equivalents and short-term investments as of March 31, 2026, are unaudited and subject to change after completion of quarter-end procedures.
BlackRock, Inc. reports beneficial ownership of 5,251,363 shares of Perspective Therapeutics Inc. common stock, representing 4.6% of the class as disclosed in this Amendment No. 1 to Schedule 13G/A. The report attributes holdings to certain Reporting Business Units of BlackRock and is signed on 04/27/2026.
Perspective Therapeutics reported updated interim results from its ongoing Phase 1/2a trial of [212Pb]VMT-α-NET in patients with advanced SSTR2-positive neuroendocrine tumors. As of the March 4, 2026 data cut-off, 64 patients had received at least one treatment across three dose cohorts.
The company highlighted a favorable safety profile with no dose-limiting toxicities, no Grade 4 or 5 adverse events, no treatment-related discontinuations, and no serious renal complications or clinically significant treatment-related myelosuppression. Grade 3 or higher treatment-emergent adverse events occurred in 23 patients, and one previously reported Grade 4 lymphopenia was revised to Grade 3.
Among two patients in Cohort 1 and 23 in Cohort 2, 18 of 25 patients (72%) were alive without progression, and 10 of 23 Cohort 2 patients (43%) had objective responses by investigator-assessed RECIST v1.1, with several showing deepening responses over time. Perspective plans further data updates in 2026 and continued regulatory engagement.
Perspective Therapeutics has issued its 2026 proxy for the Annual Meeting to be held on May 27, 2026 at 9:00 a.m. Central Time in Chicago. Stockholders of record as of April 2, 2026, when 114,017,755 common shares were outstanding, may vote.
Investors are asked to elect six directors for one-year terms, ratify WithumSmith+Brown, PC as independent auditor for 2026, and choose how often to hold advisory votes on executive pay. The Board recommends voting “FOR ALL” director nominees, “FOR” auditor ratification, and “1 YEAR” for the say‑on‑frequency proposal.